Cargando…

Homocysteinethiolactone and Paraoxonase: Novel markers of diabetic retinopathy

OBJECTIVE: Paraoxonase (PON) exhibits esterase activity (PON-AREase) and lactonase activity (PON-HCTLase), which prevent LDL oxidation and detoxify homocysteine thiolactone (HCTL). The role of HCTL and PON-HCTLase as a risk factor for the microvascular complication in diabetic retinopathy at the lev...

Descripción completa

Detalles Bibliográficos
Autores principales: Barathi, Subramaniam, Angayarkanni, Narayanasamy, Pasupathi, Aarthi, Natarajan, Sulochana Konerirajapuram, Pukraj, Rishi, Dhupper, Maneesh, Velpandian, Thirumurthy, Muralidharan, Charanya, Sivashanmugham, Muthukumaran
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928358/
https://www.ncbi.nlm.nih.gov/pubmed/20551012
http://dx.doi.org/10.2337/dc10-0132
_version_ 1782185858826240000
author Barathi, Subramaniam
Angayarkanni, Narayanasamy
Pasupathi, Aarthi
Natarajan, Sulochana Konerirajapuram
Pukraj, Rishi
Dhupper, Maneesh
Velpandian, Thirumurthy
Muralidharan, Charanya
Sivashanmugham, Muthukumaran
author_facet Barathi, Subramaniam
Angayarkanni, Narayanasamy
Pasupathi, Aarthi
Natarajan, Sulochana Konerirajapuram
Pukraj, Rishi
Dhupper, Maneesh
Velpandian, Thirumurthy
Muralidharan, Charanya
Sivashanmugham, Muthukumaran
author_sort Barathi, Subramaniam
collection PubMed
description OBJECTIVE: Paraoxonase (PON) exhibits esterase activity (PON-AREase) and lactonase activity (PON-HCTLase), which prevent LDL oxidation and detoxify homocysteine thiolactone (HCTL). The role of HCTL and PON-HCTLase as a risk factor for the microvascular complication in diabetic retinopathy at the level of vitreous has not been investigated. RESEARCH DESIGN AND METHODS: Undiluted vitreous from patients with proliferative diabetic retinopathy (PDR) (n = 13) and macular hole (MH) (n = 8) was used to determine PON-HCTLase and PON-AREase activity spectrophotometrically. HCTL levels were detected by liquid chromatography–tandem mass spectrometry. In vitro studies were done in primary cultures of bovine retinal capillary endothelial cells (BRECs) to determine the dose- and time-dependent effect of HCTL and homocysteine (Hcys) on PON-HCTLase activity, as well as to determine mRNA expression of PON by RT-PCR. RESULTS: A significant increase in HCTL and PON-HCTLase activity was observed in PDR compared with MH (P = 0.036, P = 0.001), with a significant positive correlation between them (r = 0.77, P = 0.03). The in vitro studies on BRECs showed a dose- and time-dependent increase in the PON-HCTLase activity and mRNA expression of PON2 when exposed to HCTL and Hcys. CONCLUSIONS: This is the first study showing elevated levels of vitreous HCTL and PON-HCTLase activity in PDR. These elevations are probably a protective effect to eliminate HCTL, which mediates endothelial cell dysfunction. Thus, vitreous levels of HCTL and PON activity can be markers of diabetic retinopathy. The bioinformatics analysis reveals that the structure and function of PON that can be modulated by hyperhomocysteinemia in PDR can affect the dual-enzyme activity of PON.
format Text
id pubmed-2928358
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-29283582011-09-01 Homocysteinethiolactone and Paraoxonase: Novel markers of diabetic retinopathy Barathi, Subramaniam Angayarkanni, Narayanasamy Pasupathi, Aarthi Natarajan, Sulochana Konerirajapuram Pukraj, Rishi Dhupper, Maneesh Velpandian, Thirumurthy Muralidharan, Charanya Sivashanmugham, Muthukumaran Diabetes Care Original Research OBJECTIVE: Paraoxonase (PON) exhibits esterase activity (PON-AREase) and lactonase activity (PON-HCTLase), which prevent LDL oxidation and detoxify homocysteine thiolactone (HCTL). The role of HCTL and PON-HCTLase as a risk factor for the microvascular complication in diabetic retinopathy at the level of vitreous has not been investigated. RESEARCH DESIGN AND METHODS: Undiluted vitreous from patients with proliferative diabetic retinopathy (PDR) (n = 13) and macular hole (MH) (n = 8) was used to determine PON-HCTLase and PON-AREase activity spectrophotometrically. HCTL levels were detected by liquid chromatography–tandem mass spectrometry. In vitro studies were done in primary cultures of bovine retinal capillary endothelial cells (BRECs) to determine the dose- and time-dependent effect of HCTL and homocysteine (Hcys) on PON-HCTLase activity, as well as to determine mRNA expression of PON by RT-PCR. RESULTS: A significant increase in HCTL and PON-HCTLase activity was observed in PDR compared with MH (P = 0.036, P = 0.001), with a significant positive correlation between them (r = 0.77, P = 0.03). The in vitro studies on BRECs showed a dose- and time-dependent increase in the PON-HCTLase activity and mRNA expression of PON2 when exposed to HCTL and Hcys. CONCLUSIONS: This is the first study showing elevated levels of vitreous HCTL and PON-HCTLase activity in PDR. These elevations are probably a protective effect to eliminate HCTL, which mediates endothelial cell dysfunction. Thus, vitreous levels of HCTL and PON activity can be markers of diabetic retinopathy. The bioinformatics analysis reveals that the structure and function of PON that can be modulated by hyperhomocysteinemia in PDR can affect the dual-enzyme activity of PON. American Diabetes Association 2010-09 2010-06-14 /pmc/articles/PMC2928358/ /pubmed/20551012 http://dx.doi.org/10.2337/dc10-0132 Text en © 2010 by the American Diabetes Association. https://creativecommons.org/licenses/by-nc-nd/3.0/Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ (https://creativecommons.org/licenses/by-nc-nd/3.0/) for details.
spellingShingle Original Research
Barathi, Subramaniam
Angayarkanni, Narayanasamy
Pasupathi, Aarthi
Natarajan, Sulochana Konerirajapuram
Pukraj, Rishi
Dhupper, Maneesh
Velpandian, Thirumurthy
Muralidharan, Charanya
Sivashanmugham, Muthukumaran
Homocysteinethiolactone and Paraoxonase: Novel markers of diabetic retinopathy
title Homocysteinethiolactone and Paraoxonase: Novel markers of diabetic retinopathy
title_full Homocysteinethiolactone and Paraoxonase: Novel markers of diabetic retinopathy
title_fullStr Homocysteinethiolactone and Paraoxonase: Novel markers of diabetic retinopathy
title_full_unstemmed Homocysteinethiolactone and Paraoxonase: Novel markers of diabetic retinopathy
title_short Homocysteinethiolactone and Paraoxonase: Novel markers of diabetic retinopathy
title_sort homocysteinethiolactone and paraoxonase: novel markers of diabetic retinopathy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928358/
https://www.ncbi.nlm.nih.gov/pubmed/20551012
http://dx.doi.org/10.2337/dc10-0132
work_keys_str_mv AT barathisubramaniam homocysteinethiolactoneandparaoxonasenovelmarkersofdiabeticretinopathy
AT angayarkanninarayanasamy homocysteinethiolactoneandparaoxonasenovelmarkersofdiabeticretinopathy
AT pasupathiaarthi homocysteinethiolactoneandparaoxonasenovelmarkersofdiabeticretinopathy
AT natarajansulochanakonerirajapuram homocysteinethiolactoneandparaoxonasenovelmarkersofdiabeticretinopathy
AT pukrajrishi homocysteinethiolactoneandparaoxonasenovelmarkersofdiabeticretinopathy
AT dhuppermaneesh homocysteinethiolactoneandparaoxonasenovelmarkersofdiabeticretinopathy
AT velpandianthirumurthy homocysteinethiolactoneandparaoxonasenovelmarkersofdiabeticretinopathy
AT muralidharancharanya homocysteinethiolactoneandparaoxonasenovelmarkersofdiabeticretinopathy
AT sivashanmughammuthukumaran homocysteinethiolactoneandparaoxonasenovelmarkersofdiabeticretinopathy